GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biostax Corp (OTCPK:BTAX) » Definitions » Net Income

BTAX (Biostax) Net Income : $-2.22 Mil (TTM As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Biostax Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Biostax's Net Income for the three months ended in Jun. 2024 was $-0.43 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2024 was $-2.22 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Biostax's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was $-0.01.


Biostax Net Income Historical Data

The historical data trend for Biostax's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biostax Net Income Chart

Biostax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.40 1.59 3.59 -3.54 -2.36

Biostax Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.50 -0.39 -1.05 -0.35 -0.43

Biostax Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Biostax's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-2.363+0+0+0
=-2.36

Biostax's Net Income for the quarter that ended in Jun. 2024 is calculated as

Net Income(Q: Jun. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.428+0+0+0
=-0.43

Net Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biostax  (OTCPK:BTAX) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Biostax's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Biostax Net Income Related Terms

Thank you for viewing the detailed overview of Biostax's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Biostax Business Description

Traded in Other Exchanges
N/A
Address
2431 Aloma Avenue, Suite 124, Winter Park, FL, USA, 32792
Biostax Corp is a biotechnology company utilizing the Biostax Development Engine, is a developer and marketer of pharmaceutical, biotechnology and MedTech products that have a well-defined path to market. The company is focused on driving the development and commercialization of proprietary mechanisms to prevent, intercept and improve these diseases at affordable cost. It is a therapeutic and health tech agnostic, constantly seeking assets with low acquisition costs and high growth opportunities having significant clinical and commercial potential.
Executives
Glen A Farmer officer: Chief Financial Officer 20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
H. Louis Salomonsky Jr. Revocable Trust 10 percent owner 2431 ALOMA AVE, SUITE 124, WINTER PARK FL 32792
Henry Louis Salomonsky director, 10 percent owner 2431 ALOMA AVE, SUITE 124, WINTER PARK FL 32792
Kelly O'brien Wilson 10 percent owner, officer: COO and ICEO and IP 2431 ALOMA AVE, SUITE 124, WINTER PARK FL 32792
James Norman Curley other: Member of 10% owner group 410 DAHLIA AVE, CORONA DEL MAR CA 92625
Empower Insurance Corp Ltd other: Member of 10% owner group 1254 LEEWARD HIGHWAY, 4 CARIBBEAN PLACE, PROVIDENCIALES W7 TKCA1ZZ
Global Reverb Corp 10 percent owner, other: Member of 10% owner group 100 S EOLA DR, UNIT 1703, ORLANDO FL 32801
Paul Puskadi other: Member of 10% owner group 2020 TIGERTAIL BLVD, 7A, DANIA BEACH FL 33004
Deane Rhodes other: Member of 10% owner group 9200 HALSEY CIRCLE NE, TUSCALOOSA AL 35406
Roger Dale Bozarth other: Member of 10% owner group 9028 GREAT HERON CIR, ORLANDO FL 32836
Joel Yanowitz other: Member of 10% owner group 100 TAMAL PLZ, SUITE 106, CORTE MADERA CA 94925
Rogoff Family Trust Dtd other: Member of 10% owner group 20701 N SCOTTSDALE DR, ST 107-501, SCOTTSDALE AZ 85255
George Sasko other: Member of 10% owner group 515 WESTCHESTER DR, STE D, CAMPBELL CA 95008
Raster Investments, Inc other: Member of 10% owner group 2384 ORCHARD CREST BLVD, MANASQUAN NJ 08736
Robert Jackman Dailey other: Member of 10% owner group 401 FIRST STREET, LOS ALTOS CA 94022

Biostax Headlines

From GuruFocus

Immune Therapeutics Revises and Resends Proxy Statement

By Marketwired Marketwired 09-10-2019